Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2012

Open Access 01-02-2012 | Review

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations

Authors: Christina Kaiser, Ann Knight, Dan Nordström, Tom Pettersson, Jonas Fransson, Ebba Florin-Robertsson, Björn Pilström

Published in: Rheumatology International | Issue 2/2012

Login to get access

Abstract

Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.
Literature
1.
Zanette D et al (1998) Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification. J Biotechnol 64(2–3):187–196PubMedCrossRef
2.
Arend WP, Gabay C (2000) Physiologic role of interleukin-1 receptor antagonist. Arthritis Res 2(4):245–248PubMedCrossRef
3.
Clarke JB Mechanisms of adverse drug reactions to biologics. Handb Exp Pharmacol (196):453–474
4.
Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36(6):1118–1125PubMedCrossRef
5.
Bendele A et al (1995) Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications. J Lab Clin Med 125(4):493–500PubMed
6.
Cohen S et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614–624PubMedCrossRef
7.
Raibekas AA et al (2005) Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. Biochemistry 44(29):9871–9879PubMedCrossRef
8.
Wang YC, Kowal RR (1980) Review of excipients and pH’s for parenteral products used in the United States. J Parenter Drug Assoc 34(6):452–462PubMed
9.
Fransson J, Espander-Jansson A (1996) Local tolerance of subcutaneous injections. J Pharm Pharmacol 48(10):1012–1015PubMedCrossRef
10.
Frenken LA et al (1993) Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis 22(4):553–556PubMed
11.
Laursen T, Hansen B, Fisker S (2006) Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 98(2):218–221PubMedCrossRef
12.
Steele RH et al. (2005) Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 10(3):317–320
13.
Konttinen L et al (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25(6):882–884PubMedCrossRef
14.
den Broeder AA et al (2006) Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 65(6):760–762CrossRef
15.
Karanikolas G et al (2008) Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology (Oxford) 47(9):1384–1388CrossRef
16.
Vila AT et al (2005) Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 153(2):417–423PubMedCrossRef
17.
Saunders C et al. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs 42(5 Suppl):S10-S8
18.
Moustou AE et al (2009) Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 61(3):486–504PubMedCrossRef
19.
Winfield H et al (2006) Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol 142(2):218–220PubMedCrossRef
20.
Rivkin A (2009) Certolizumab pegol for the management of Crohn’s disease in adults. Clin Ther 31(6):1158–1176PubMedCrossRef
21.
Assanasen P, Naclerio RM (2002) Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin Allergy Immunol 17:101–139PubMed
22.
Minai-Fleminger Y, Levi-Schaffer F (2009) Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res 58(10):631–638PubMedCrossRef
23.
Lin CH, Lai YL (2005) Mast cell mediators in citric acid-induced airway constriction of guinea pigs. Toxicol Appl Pharmacol 206(3):343–350PubMedCrossRef
24.
Bresnihan B et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12):2196–2204PubMedCrossRef
25.
Nuki G et al (2002) Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(11):2838–2846PubMedCrossRef
26.
Fleischmann RM (2003) Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl 2):ii29–35
27.
Cohen SB et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062–1068PubMedCrossRef
28.
Fleischmann RM et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006–1012PubMedCrossRef
29.
Le Loet X et al (2008) Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial. J Rheumatol 35(8):1538–1544PubMed
Metadata
Title
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
Authors
Christina Kaiser
Ann Knight
Dan Nordström
Tom Pettersson
Jonas Fransson
Ebba Florin-Robertsson
Björn Pilström
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2096-3

Other articles of this Issue 2/2012

Rheumatology International 2/2012 Go to the issue

Original Article

Thyroid autoimmunity may represent a predisposition for the development of fibromyalgia?

Review Article

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

Original Article

Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings

Case Report

Perivascular carotid inflammation: an unusual case of carotidynia

Original Article

Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus

Original Article

Effects of extracorporal shock wave therapy on symptomatic heel spurs: a correlation between clinical outcome and radiologic changes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits